All Articles

The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib. Read More ›

In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma. Read More ›

In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib. Read More ›

Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved. Read More ›

Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment. Read More ›

The Meet-URO score combines inflammatory and clinical markers to predict response to nivolumab. Read More ›

In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy. Read More ›

Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability. Read More ›

Stereotactic radiotherapy for oligoprogressive tumors while on oral systemic therapy delays time to treatment switch. Read More ›

A 14-mg starting dose of lenvatinib did not improve tolerability and had numerically worse efficacy than the approved 18-mg dose. Read More ›